Education
About Us
Working with TipRanks
Follow Us
QEFA - ETF AI Analysis
Top Page
SPDR MSCI EAFE StrategicFactors ETF (QEFA)
Rating:65Neutral
Price Target:
$93.00
Positive Factors
Strong Top Holdings
Several of the largest positions, such as ASML Holding NV and Nestlé SA, have shown strong year-to-date performance, supporting the fund’s overall returns.
Global Diversification
The ETF provides exposure to a wide range of countries, including Japan, the UK, and Switzerland, reducing reliance on any single geographic market.
Reasonable Expense Ratio
With an expense ratio of 0.3%, the fund offers relatively low costs compared to actively managed alternatives.
Negative Factors
Underperforming Holdings
Some top holdings, such as Unilever and Shell, have delivered weaker year-to-date performance, which could drag on overall returns.
Sector Concentration Risk
The ETF has significant exposure to Financials and Industrials, which may increase vulnerability if these sectors face challenges.
Limited U.S. Exposure
With only 3.48% of assets allocated to U.S. companies, the fund may miss out on growth opportunities in the world’s largest economy.
QEFA vs. SPDR S&P 500 ETF (SPY)
AUM967.04M
RegionDeveloped Markets
Expense Ratio0.30%
Beta0.57
IssuerSPDR
Inception DateJun 04, 2014
Dividend Yield2.84%
Asset ClassEquity
Index TrackedMSCI EAFE Factor Mix A-Series (USD)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume48,828
30 Day Avg. Volume44,184
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
96.55Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering661
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
QEFA Summary
The SPDR MSCI EAFE StrategicFactors ETF (Ticker: QEFA) is an investment fund that focuses on stocks from developed countries outside North America, such as Japan, the UK, and Australia. It follows the MSCI EAFE Factor Mix A-Series Index, which selects companies based on factors like value, quality, and low volatility. Some well-known companies in this ETF include Nestlé and AstraZeneca. Investors might consider QEFA for diversification and exposure to stable international markets. However, since it invests heavily in foreign markets, its performance can be affected by global economic conditions and currency fluctuations.
How much will it cost me?The SPDR MSCI EAFE StrategicFactors ETF (Ticker: QEFA) has an expense ratio of 0.3%, meaning you’ll pay $3 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed to incorporate multiple investment factors like value, low volatility, and quality into its strategy.
What would affect this ETF?The QEFA ETF, which focuses on developed markets outside North America, could benefit from stable economic growth in Europe and Asia, as well as increased demand for high-quality and low-volatility stocks in sectors like healthcare and consumer defensive. However, it may face challenges from rising interest rates, which could pressure financial and real estate sectors, and geopolitical tensions or regulatory changes in its key regions could negatively impact its top holdings and overall performance.
QEFA Top 10 Holdings
The SPDR MSCI EAFE StrategicFactors ETF (QEFA) leans heavily on developed markets outside North America, with a notable focus on healthcare and financial sectors. Roche and AstraZeneca are rising stars, delivering steady gains thanks to strong pipelines and strategic growth, while Nestlé’s performance has been more mixed, weighed down by valuation concerns. ASML, a key player in technology, is losing steam after earlier momentum, which could drag on the fund. Overall, QEFA’s sector diversity provides balance, but its reliance on healthcare and financial heavyweights shapes its trajectory.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 2.26% | $21.78M | €328.62B | 34.84% | 76 Outperform | |
| Novartis AG | 2.00% | $19.30M | CHF199.04B | 12.04% | 80 Outperform | |
| AstraZeneca | 1.90% | $18.31M | £218.59B | 34.39% | 76 Outperform | |
| Roche Holding AG | 1.82% | $17.58M | CHF250.94B | 33.10% | 73 Outperform | |
| Nestlé SA | 1.76% | $16.99M | CHF202.01B | 15.24% | 71 Outperform | |
| Shell (UK) | 1.33% | $12.85M | £158.51B | 8.28% | 77 Outperform | |
| Unilever | 1.33% | $12.83M | £111.61B | -2.98% | 77 Outperform | |
| GlaxoSmithKline | 1.10% | $10.60M | £72.49B | 33.23% | 82 Outperform | |
| Zurich Insurance Group | 1.04% | $9.99M | CHF80.64B | 13.72% | 78 Outperform | |
| LVMH Moet Hennessy Louis Vuitton | 0.97% | $9.33M | €307.85B | 4.71% | 78 Outperform |
QEFA Technical Analysis
Positive
―
Price Trends
87.11
Positive
85.92
Positive
82.46
Positive
Market Momentum
-0.09
Positive
52.87
Neutral
13.60
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QEFA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 87.28, equal to the 50-day MA of 87.11, and equal to the 200-day MA of 82.46, indicating a bullish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 52.87 is Neutral, neither overbought nor oversold. The STOCH value of 13.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QEFA.
QEFA Peer Comparison
Comparison Results
Performance Comparison
QEFA
SPDR MSCI EAFE StrategicFactors ETF
87.62
15.75
21.91%
GSID
Goldman Sachs MarketBeta International Equity ETF
―
―
―
JHMD
John Hancock Multifactor Developed International ETF
―
―
―
IQDG
WisdomTree International Quality Dividend Growth Fund
―
―
―
DMXF
iShares ESG Advanced MSCI EAFE ETF
―
―
―
NUDM
Nuveen ESG International Developed Markets Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents